UNSPSC 51372022: Buprenorphine hydrochloride

This classification denotes an opioid receptor agonist and opioid, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 56W8MW3EN1. European Medicines Agency schedules Buprenorphine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13133MIG. Buprenorphine hydrochloride generally arises in the molecular formula C29H41NO4.CLH. The term 'buprenorphine hydrochloride' is a United States Adopted Name designation.

UNSPSC 51372022 Buprenorphine hydrochloride is a Commodity code that encompasses opioid-agonist medications and related pharmaceutical products acquired by state and local health agencies, public health departments, and cooperative purchasing alliances to support medication-assisted treatment programs, community health initiatives, and emergency response systems. State and local governments are procuring buprenorphine and related therapeutics through a mix of direct purchasing (county health departments), state-level cooperative purchasing vehicles, and intergovernmental alliances that aggregate demand across multiple jurisdictions. The issuing bodies range from county community health programs to state health and human services commissions and multistate cooperative purchasing organizations, reflecting both point-of-care procurement and centralized, networked purchasing models designed to achieve scale economies and standardized pricing across geographies.

Recent activity shows Seminole County, Florida (IFB 60459723LAS, due July 26, 2023) procuring naloxone through competitive sealed bidding, though the solicitation also includes drug deactivation systems alongside the primary pharmaceutical acquisition. The Texas Health and Human Services Commission (RFI HHS0017013, posted April 3, 2026) is in early-stage market intelligence gathering for direct-to-manufacturer prescription programs to improve cost management and fulfillment efficiency outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) (RFP S1070000015802, due March 26, 2026) is establishing multiple-award contracts for generic multi-source pharmaceuticals and over-the-counter products, requiring manufacturers to supply through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) with pricing effective July 1, 2026, and participation extending to Oregon and other allied jurisdictions. Geographic activity centers on Florida, Texas, and Minnesota-anchored multistate coalitions, with MMCAP's cooperative model suggesting broader regional participation. Evaluation priorities in recent RFPs emphasize price competitiveness, cGMP and DSCSA compliance, EDI capability, and insurance coverage requirements.